Spontaneous bleeding and poor bleeding response with extended half‐life factor IX products: A survey of select US haemophilia treatment centres

Page 1

	Year	Citations
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B Jerry S. Powell, John Pasi, Margaret V. Ragni, New England Journal of Medicine	2013	347
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B Claude Négrier, Karin Knobe, Andreas Tiede, Blood	2011	179
Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo Tong Gui, Hui-Feng Lin, Da-Yun Jin, Blood	2002	86
Identification of the endothelial cell binding site for factor IX. Wing-Fai Cheung, J van den Born, K. Kühn, Proceedings of the National Academy of Sciences Factor IxVascular DiseaseEndothelial CellsCollagen IvImmunology	1996	85
Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV Ting Gui, Heyu Ni, Peter L. Gross, Journal of Thrombosis and Haemostasis InflammationFactor IxKnockout MouseDisease MechanismHematology	2009	61
<i>In vivo</i> evidence of intravascular binding sites for coagulation factor IX David M. Stern, Glen Knitter, W Kisiel, British Journal of Haematology	1987	49
Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients U. Martinowitz, Toshko Lissitchkov, Aaron Lubetsky, Haemophilia	2015	39

Page 1